Drugs / Nefecon
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT05534919 | Dec 2022 → Jul 2024 | IgA glomerulonephritis | Everest Medicines (Singapore) Pte. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04541043 | Nov 2020 → Feb 2024 | IgA glomerulonephritis | Calliditas Therapeutics AB | Completed | No outcome recorded |
| Phase 3 | NCT03643965 | Sep 2018 → Jul 2023 | IgA glomerulonephritis | Calliditas Therapeutics AB | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07604311 | May 2026 → Dec 2028 expected | IgA glomerulonephritis | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nefecon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03643965 ↗ |
| Action | Inhibit | “designed to inhibit galactose-deficient IgA1 formation underlying IgAN pathophysiology” PMID 39724565 ↗ Oct 2024 |
| Route | Oral | “Nefecon 16 mg for daily administration by mouth for 9 months.” NCT03643965 ↗ |